1. Introduction {#s0005}
===============

Epigenetics is important in regulating the differentiation of different types of cells in both prenatal and postnatal development. It is the mechanism by which the expression of genes in the genome can be regulated without altering the base sequence of DNA. This includes chromatin remodeling, DNA methylation, histone modifications and the expression of non-coding RNA ([@bb0295]). Epigenetics regulate changes in gene expression and determine the fate of cells in response to environmental, developmental and metabolic cues ([@bb0010]). Of the epigenetic mechanisms mentioned above, histone modification by acetylation has been shown to be important for regulating cellular function ([@bb0185]).

Histone modification by acetylation is able to induce an open chromatin structure, which correlates with gene activation. Histone deacetylation, however, results in a condensation of chromatin which is related to transcriptional repression. These two processes, acetylation and deacetylation, are controlled by two distinctive groups of enzymes: histone acetyltransferases (HATs) and histone deacetylases (HDACs) ([@bb0030], [@bb0060]). Different HATs/HDACs display different mechanisms of histone substrate binding and catalysis. In general, HATs transfer an acetyl group onto lysine residues of histone tails while HDACs remove acetyl group leading to histone hypoacetylation. Inhibition of HDACs accelerated osteoblast differentiation but decreased osteoclastogenesis ([@bb0035], [@bb0255], [@bb0320]). This was found with different cell types such as osteoblasts, bone marrow mesenchymal cells, adipose-derived stromal cells, and macrophages ([@bb0035], [@bb0255], [@bb0320]). Study demonstrated the important role of HDACs in maintaining the balance between osteoblastic bone formation and osteoclastic bone resorption; processes crucial for bone tissue homeostasis ([@bb0065]). During the course of osteogenic differentiation of mesenchymal pre-osteoblasts with an HDAC inhibitor, osteoblast-related gene expression, and bone nodule formation were accelerated ([@bb0150]). *In vivo* bone regeneration potential of periodontal ligament-derived pre-osteoblasts in mouse calvaria defects was also enhanced by pretreating these cells with an HDAC inhibitor ([@bb0150], [@bb0155]). These data indicate HDACs as important epigenetic factors that drive mineral tissue regeneration.

2. Epigenetics and histone acetylation {#s0010}
======================================

Epigenetic mechanisms are able to regulate nuclear activities which are crucial for certain cellular activities associated with cell fate determination including gene transcription, DNA repair and replication. Hence, they play a role in cell maintenance and differentiation ([@bb0345]).

Nucleosomes are the basic molecular units of chromatin. They consist of 145--147 bp of DNA and are wrapped nearly twice around a histone octamer. The histone octamers are composed of two molecules of each histone H2A, H2B, H3, and H4. Histone H1 is positioned adjacent to the nucleosomes *via* a linker. The histones are required for folding of DNA to form the higher-order chromatin structure. This chromatin structure is dynamic and can be switched back and forth between loosely packed euchromatin, and tightly packed heterochromatin. The loosely packed euchromatin is more accessible for the transcriptional apparatus to bind and activate transcription of particular genes. The structure of tightly packed heterochromatin physically limits access of transcriptional complexes to DNA which leads to transcriptional inactivity ([Fig. 1](#f0005){ref-type="fig"}) ([@bb0005]). The transition between the euchromatin and heterochromatin state is partly regulated by epigenetic mechanisms which require concert action of chromatin-modifying enzymes. Among these epigenetic mechanisms, acetylation is the only modification that directly causes a structural relaxation of chromatin by neutralizing the charge of histones ([@bb0120]). Other modifications such as histone methylation, phosphorylation act as docking sites that promote recruitment and stabilization of effector protein complexes. The H3 and H4 histone tails are the main targets for acetylation and methylation, primarily at lysine and arginine residues. Methylation and acetylation of specific lysine residues on histones have defined roles in regulating gene expression by recruiting other protein complexes for transcription ([@bb0020], [@bb0115]).Fig. 1Nucleosome and chromatin modification *via* histone acetylation. A) A nucleosome includes DNA wrapping around a histone octamer, containing two molecules of each histone H2A, H2B, H3, H4; acetyl group such as Lysin 9 (K9) on histone tail. B) Transcriptional inactivation and activation *via* the acetylation of histones which controls by HAT (activation) and HDAC (inactivation). HATs transfer the acetyl moiety to histone tail and HDACs remove this group from the histones comprising the nucleosome.Fig. 1.

There are several important positions for acetylation including Lys9, Lys14, Lys27 on histone H3, and Lys5, Lys8, Lys12 and Lys16 on histone H4, which are involved in the formation of permissive chromatin structure ([@bb0025], [@bb0330]). In general, there are three possible mechanisms by which histone acetylation regulates transcription ([@bb0275]). Acetylation of specific lysine residues in the histone tails neutralizes its positive charge and unwinds the DNA-histone interactions ([@bb0120]). Acetylation also serves as a signal that recruits certain chromatin or transcription-associated proteins called bromodomains to specifically read the signal and render chromatin remodeling resulting in the activation of transcription ([@bb0335]). Lastly, histone tails undergo modifications in various ways for example acetylation, methylation, phosphorylation and ubiquitination. These histone tail modifications form a code that is read by cellular machineries. This code is called "histone code" which serves as chromatin-template beyond the genetic code of the DNA template. In detail, distinct histone amino-terminal modifications can generate synergistic or antagonistic interaction affinities for chromatin-associated proteins, which in turn dictate dynamic transitions between transcriptionally active or transcriptionally silent chromatin states ([@bb0275], [@bb0165]).

3. The function of histone acetylases and deacetylases {#s0015}
======================================================

As indicated above, the acetylation and deacetylation of histones is controlled by HATs and HDACs, respectively. HATs transfer an acetyl group from acetyl coenzyme A (acetyl-CoA) onto the ε-amino groups of conserved lysine residues within the core histones. Based on their cellular origin and function, the HATs family is divided into two different classes, type A and type B. Type A HATs locate in the nucleus and are involved in the regulation of gene expression through acetylation of nucleosomal histones. Type B HATs are located in the cytoplasm and are responsible for acetylating newly synthesized histones, which are then transported from the cytoplasm to the nucleus before their interaction with newly replicated DNA. Type A HATs contain a bromodomain which helps these enzymes to recognize and bind to acetylated lysine residues on histone substrates. The acetyl groups added by type B HATs to the histones are removed by HDACs once they enter the nucleus, but before their incorporation into chromatin ([@bb0250]).

The eighteen members of the human HDACs family are divided into two groups based on their Zn^2 +^ and NAD^+^-dependency. The Zn^2 +^-dependent subfamily includes the class I HDACs (HDAC 1, 2, 3, and 8) that are widely expressed in many cell types ([@bb0280]). Class IIa (HDAC 4, 5, 7, 9), class IIb (HDAC 6 and 10) and class IV (HDAC 11) are expressed in a more tissue-specific fashion ([Table 1](#t0005){ref-type="table"}). The Zn^2^-dependent members of HDACs remove acetyl group from the histones comprising the nucleosome leading to histone hypoacetylation. This results in a smaller space between the histones and the DNA wrapped around it. In addition to histone modification, some HDACs can act on non-histone proteins as well. For example, inhibition of HDAC decelerated the acetylation of HSP90 by inhibiting its associated HDAC6. This resulted in a limitation of HSP90 chaperone function ([@bb0070]). Using vorinostat to inhibit HDACs altered about 10% of acetylation sites in a total of 3600 lysine acetylation sites on 1750 proteins ([@bb0045]). Regulated mainly by acetyltransferase, lysine acetylation sites in proteins were proven to play an important role in diverse cellular processes, such as chromatin remodeling, cell cycle progression, splicing, nuclear transport, actin nucleation as well as in gene expression, DNA damage repair, cytoskeleton function, protein chaperone, and ribosome formation and function ([@bb0045], [@bb0125]).Table 1Summary of Zn^2 +^-dependent HDACs subfamilies. SM---skeletal muscle; B---brain; PL---platelet; L---liver; K---kidney; S---spleen; H---heart; PA---pancreas.Table 1.HDACLocalizationMajor tissue distributionFunction (partly)*Class I* HDAC 1NucleusUbiquitousTranscriptional repression\
Cell survival, proliferation and differentiation HDAC 2 HDAC 3 HDAC 8Suppress osteogenic differentiation*Class IIa* HDAC 4Nucleus/cytoplasmH, SM, BTranscriptional repression\
Chondrocyte and osteocyte development differentiation HDAC 5Transcriptional repression\
Muscle differentiation block\
Cardiac and vascular endothelial function HDAC 7H, PL, PA, SMInhibit osteoclast differentiation\
Thymocyte differentiation HDAC 9SM, B*Class IIb* HDAC 6Mainly cytoplasmH, L, K, PATubulin-deacetylase HDAC 10L, S, KUnknown*Class IV* HDAC 11Nucleus/cytoplasmB, H, SM, KImmuno-regulation(Modified from [@bb0280] and [@bb0210])

To inhibit HDACs by blocking access to their active site, several natural and synthetic inhibitors have been identified. Typically, HDAC inhibitors contain similar structural characteristics including: a zinc-binding group which coordinates the zinc ion in the active site, a cap substructure which interacts with amino acids at the entrance of the *N*-acetylated lysine binding channel of HDAC, and a linker connecting the cap and the zinc-binding group at a proper distance ([Fig. 2](#f0010){ref-type="fig"}) ([@bb0280]). Inhibitors function by displacing the zinc ion at the catalytic domain of HDAC and thereby rendering the charge-relay system dysfunctional. The inhibitors can be divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids, and benzamides ([@bb0060], [@bb0280]).Fig. 2Structural characteristics of HDAC inhibitors and the example structure of Trichostatin A (TSA). The CO and OH groups are thought to chelate the zinc ion in the active site of HDAC in a bidentate fashion.Fig. 2.(Modified from [@bb0280])

HDAC inhibitors induce an accumulation of acetylated histones and other non-histone proteins. The structural alteration of histone proteins alters several biological processes including regulation of gene expression, cell proliferation, cell migration, and cell death. The exact mechanisms involved in these processes are not fully understood. Owing to the effect in regulating cellular function, many studies demonstrated that HDAC inhibitors can cure cancer, inflammation, and nerve degradation after brain injury *in vivo* ([@bb0340], [@bb0050], [@bb0315], [@bb0285], [@bb0205]). Some of the inhibiting compounds have entered into clinical trials such as Trichostatin A (TSA), sodium butyrate (NaB), SAHA, phenylbutyrate, depsipeptide, pyroxamide, valproic acid (VPA). In addition to pan-inhibitors which act on many HDAC members leading to a wide range of effects in patients, a number of selective HDAC inhibitors are effortful studied that could be advantageous for specific clinical use ([@bb0315]).

4. Histone deacetylase role in mineralized tissue formation {#s0020}
===========================================================

4.1. Role of HDACs in osteoblasts and MSCs {#s0025}
------------------------------------------

HDACs have been shown to be involved in osteoblast differentiation and maturation ([@bb0310], [@bb0290], [@bb0325], [@bb0305]). Besides their effect on histone proteins, HDACs also catalyze deacetylation of non-histone proteins especially of transcription factors that drive bone formation. Posttranslational modifications, such as acetylation, of these transcription factors can alter their transcriptional activity and stability. Several studies have reported the interaction of RUNX2, the important transcription factor regulating osteoblast phenotypes, with HDACs and these interactions seem to be crucial for modulating osteoblastic differentiation. For example, Westendorf et al. showed that HDAC6 binds to Runx2 in differentiating osteoblasts and this interaction is necessary for repression of the p21 promoter in preosteoblasts ([@bb0310]). HDAC 1 and 3 are transcriptional co-repressors of osteoblast differentiation by interacting with RUNX2, to modulate its downstream genes like osteocalcin ([@bb0260], [@bb0190]). Several studies showed that HDAC 3 can bind to RUNX2, nuclear factor of activated T cells (NFATc1), T-cell factor (TCF) and zinc finger protein 521 (Zfp521). These bindings seem to regulate osteoblast differentiation by suppressing osteoblast-related gene expression ([@bb0260], [@bb0040], [@bb0135]). Being reported as a novel transcriptional co-repressor of Runx2, HDAC7 associates with Runx2 and represses its transcriptional activity. Runx2 repression induced by HDAC7 occurs in a deacetylase-independent manner in which the catalytic domain of HDAC 7 is not required thus demonstrating a distinctive action of HDAC7 ([@bb0160]).

Besides direct interaction with transcriptional factor, HDACs have also been reported to exert their functions by regulating chromatin structure which results in the modification of transcriptional activity of osteoblast-related genes. During osteoblast differentiation, recruitment of HDAC 1 to the promoter regions of osterix and osteocalcin decreased, whereas recruitment of p300, a HAT, to those promoters was enhanced remarkably ([@bb0190]). Studies showed that histone H3 and H4 acetylation at promoter and coding regions of the osteocalcin gene were associated with osteocalcin transcriptional activation in mature osteoblasts. The results suggest a functional linkage of histone H3 and H4 acetylation that renders chromatin remodeling across specific regions of the OCN promoter accompanying with tissue-specific transcriptional activation ([@bb0265], [@bb0270]). During normal osteoblast differentiation, hyperacetylation of histones has been noted at the osteocalcin gene promoter and the acetylation increased under the influence of an HDAC inhibitor ([@bb0325], [@bb0270], [@bb0140]). The increase of histone H3 acetylation at lysines K9/K14 during osteogenic differentiation induced by inhibition of HDAC activity even enhanced the process ([@bb0150]). As mentioned, epigenetics including histone acetylation plays an important role in cell proliferation and differentiation. Among these, histone modification by acetylation regulates osteogenesis by mesenchymal cells. Osteogenic differentiation of human adipose tissue-derived stromal cells, bone marrow stromal cells, and MC3T3-E1 cells have been shown to be accelerated by several types of HDAC inhibitors including VPA, TSA, and NaB ([Table 2](#t0010){ref-type="table"}) ([@bb0255], [@bb0320]). With human mesenchymal stem cells (hMSCs), an HDAC inhibitor can promote or inhibit cell differentiation ([@bb0195]). Despite being inefficient to boost adipogenic, chondrogenic, and neurogenic differentiation, VPA and NaB did enhance osteogenic differentiation. For example, HDAC inhibitors can block adipogenesis by affecting the acetylation state of adipogenic transcription factors C/EBPβ, ultimately reducing its DNA-binding affinity and transcriptional activation potential ([@bb0130]).Table 2The effect of HDAC inhibitors on osteogenesis and osteoclastogenesis of various cell types.Table 2.InhibitorCell typeEffectMechanismRefVPAAdipose\
Bone marrowOsteogenesisIncrease OSX, OPN, BMP2, RUNX2, ALP([@bb0035])VPABone marrow stromal cellsOsteogenesisIncrease acetylation of H3K9 *via* HDAC 8 regulation([@bb0170])VPADental pulp stem cellsOsteogenesisDown-regulate HDAC 2\
Increase OC, BSP, and OPN([@bb0265])VPA\
NaBAdipose\
Umbilical cordOsteogenesisIncrease p21CIP1/WAF1([@bb0195])VPA\
NaBAdipose-derived stromal cellsOsteogenesisIn reduced oxygen tension([@bb0320])NaBPrimary bone marrow cellsOsteogenesisRegulation of HDAC1\
Increase Runx2, OC, OPN, and ALP([@bb0135])VPA\
TSAMurine dental pulp--derived cell lineOsteogenesisIncrease DMP-1, BMP-4([@bb0075])TSADental pulp stem cellsOdontoblast differentiationUp-regulate phospho-Smad2/3, Smad4, and nuclear factor I-C([@bb0175])TSAHuman periodontal ligament cellsOsteogenesis bone regenerationReduction of HDAC1, 2, 3\
Increase acetylation of H3K9K14 and RUNX2([@bb0150])SAHAOsteoblast precursor\
Primary osteoblastOsteogenesisIncreased MMP-13([@bb0085])

HDAC inhibitors could induce the expression of osteotropic factors such as *BMP-2* and *BMP-4* by hMSCs and ADSCs (adipose tissue-derived stem cells) ([@bb0325], [@bb0140]). Several HDAC inhibitors such as NBu, VPA, TSA, CHAP27 and SCOP402 also up-regulated RUNX2 protein and its acetylation ([@bb0150], [@bb0180], [@bb0105], [@bb0170]). The increase in acetylation level of this protein has been shown to correlate with a functional increase since RUNX2 acetylation is required for its transcriptional activity ([@bb0170]). Together, the data indicate that inhibition of HDAC sufficiently promotes osteogenic differentiation of mesenchymal cells but different HDAC forming complexes with various transcription-related proteins may have distinct roles during the process ([@bb0305]).

4.2. Role of HDACs in tooth-derived cells {#s0030}
-----------------------------------------

Similar to mesenchymal cells, dental-derived stem cells (DPSCs) have drawn attention because of their accessibility, plasticity, and high proliferative ability ([@bb0145]). In fact, these cells are osteoblast-like and are able to differentiate into osteo/odontoblasts under appropriate stimulation ([@bb0095], [@bb0110], [@bb0100]). These cells as well as periodontal ligament cells (PDLCs) display a great potential for cell-based tissue engineering, especially for bone regeneration ([@bb0245]) ([Fig. 3](#f0015){ref-type="fig"}). Studies showed that HDAC inhibitors such as NaB and VPA up-regulated osteoblast-related gene expression of DPSCs ([@bb0230]). VPA was shown to enhance matrix mineralization by increasing *OPN* and *BSP* expression; an effect that correlated with inhibition of HDAC 2 ([@bb0230]). TSA, another pan HDAC inhibitor, promoted proliferation and differentiation of odontoblasts *via* an up-regulation of phospho-Smad2/3, Smad4, and nuclear factor I-C in DPSCs ([@bb0175]). VPA and TSA promoted osteogenic differentiation of DPSCs *via* an increased expression of DMP-1, BMP-2/-4 and Nestin ([@bb0080]). In a murine dental pulp-derived cell line (MDPC-23), VPA and TSA significantly increased the expression of dentine matrix protein-1 ([@bb0075]). In both a dental-papillae derived cell-line and primary DPSCs, HDAC inhibitor-induced expression of specific dentin marker genes was demonstrated. This may result in an increase in mineralization ([@bb0075], [@bb0085]). For example, VPA and TSA induced p21WAF1/CIP and DMP-1 expression leading to enhanced mineralization. SAHA, another pan HDAC inhibitor, promoted mineralization and migration in DPSCs by inducing the expression and activity of metalloproteinase (MMP)-13. The latter enzyme may influence cell migration and cleave matrix-bound dentin matrix proteins to increase chemotaxis and differentiation of pulp cells at the injury site ([@bb0075], [@bb0085]).Fig. 3Suggested expression fashion of bone related markers and HDACs in hPDLs ([@bb0150], [@bb0180]) A) and DPSCs ([@bb0230], [@bb0175]) B) during odonto-osteogenic differentiation. (RUNX2, runt-related transcription factor 2; OSX: osterix; COL1, type I collagen; ALP, alkaline phosphatase; BSP, bone sialoprotein; OCN, osteocalcin; OPN, osteopontin; DMP1, dentin matrix acidic phosphoprotein 1; DSPP, dentin sialophosphoprotein; SOST, sclerostin; Ac: acetylation; H3: Histone H3; K9, K14: Lysine 9, 14.)Fig. 3.

Recently, we reported the expression of HDACs by human PDLCs (hPDLCs) and some of these enzymes, predominantly class I (HDAC 1, 2, 3) were down regulated during osteogenic differentiation. Culturing of hPDLCs with TSA resulted in an increased acetylation of H3K9K14 (Histone H3, Lysine 9, 14), and RUNX2 which associated with an increased expression of bone-related genes ([@bb0150]). TSA enhanced *in vivo* bone formation by hPDLCs in a mouse calvarial defect model ([@bb0155]). These findings strongly suggest a role of these enzymes in modulating the osteogenic differentiation potential of hPDLCs signifying attractive candidates for regenerative therapy ([Fig. 4](#f0020){ref-type="fig"}). Likewise, TNF-α stimulated PDL stem cells had a high expression of HDACs. Inhibition the enzymes activity by TSA significantly promoted the osteogenic differentiation potential of the cells in inflammatory microenvironment ([@bb0300]). The expression pattern of HDACs along with bone related markers during the course of osteogenic differentiation of hPDLs and DPSCs are schematically shown in [Fig. 3](#f0015){ref-type="fig"}. This data might emphasize a specific role of these enzymes in distinctive sets of dental-derived cells during odonto-osteogenic differentiation ([@bb0150], [@bb0155], [@bb0175]).Fig. 4Mechanism of HDAC inhibitor TSA in osteogenic differentiation of hPDLCs. TSA inhibits HDAC enzymes, including the reduction of HDAC1, 2, 3 leading to the acetylation of H3K9K14 and production and acetylation of RUNX2 and which activate bone-related gene expression. Then, the cells go to osteogenesis (H3: Histone H3; K9, K14: Lysine 9, 14) ([@bb0150], [@bb0155]).Fig. 4.

5. HDAC application in mineralized tissue regenerative therapy {#s0035}
==============================================================

Up to date, several HDAC inhibitors are used in clinical trials to cure diseases such as cancer, inflammation, and nerve degradation after brain injury ([@bb0340], [@bb0315], [@bb0285], [@bb0055]). These inhibitors are also considered in tissue engineering like bone regeneration therapy. Tissue engineering involves the replacement of organs or the repair of damaged tissues. Bone graft substitutes are materials used to form/replace bone in the body. Recent technology mainly focused on improving the osteogenic potential of bone grafting materials either by incorporating osteoprogenitor cells or growth factors into a scaffold made of various materials ([@bb0235]).

Paino et al. investigated the response of DPSCs to VPA in an environment that mimicked 3D bone tissue ([@bb0230]). In the samples pre-treated with VPA, collagen and calcium deposits were much more intense and diffusely distributed in a rotating collagen scaffold system. Schroeder and Westendorf showed that HDAC inhibitors promoted osteoblast maturation in calvariae by increasing their ALP activity *ex vivo* ([@bb0255]). Recently, Huynh et al., demonstrated that a treatment with a single dose of TSA enhanced mineral deposition of hPDLCs in a polycaprolactone/polyethylene glycol (PCL/PEG) scaffold *in vitro* ([@bb0155]). For in vivo bone regeneration, intraperitoneal injection of vorinostat into C57BL mice increased serum osteocalcin levels and osteoblast numbers of endocortical and trabecular bone surfaces ([@bb0325]). Jin et al. demonstrated that TSA affected odontoblast differentiation and dentin formation by inducing an increased number of odontoblasts, thicker dentin and a higher DSP expression ([@bb0175]). Because HDAC suppression enhances osteogenic differentiation, it seems possible to develop tissue-targeted inhibitors for treatment of bone-related diseases or a controlled release inhibitor for bone regenerative treatment.

Recently, Neves et al. introduced a model of collagen sponges to deliver low doses of glycogen synthase kinase (GSK-3) antagonists to promote the natural processes of reparative dentine formation ([@bb0225]). The study shares the similar approach with our previous study on using HDAC inhibitor-loaded scaffold for bone regeneration *in vivo* ([@bb0155]). These relatively simple methods potentially provide a novel approach for repair of the tooth/dentin structure. Several studies reported a role of HDAC inhibitors in odontoblast differentiation and dentin formation *in vitro* and *in vivo* ([@bb0175], [@bb0085]). HDAC inhibitor-induced DPSC promoted the mineralization and migration, thus proposing HDAC inhibitors as potential candidate molecules to induce nearby progenitor cells in the pulp to differentiate and to participate in the formation of reparative dentine ([@bb0175], [@bb0085]). This highlights the potential benefit of applying HDAC inhibitors to damaged tissue during regenerative dentin therapy ([@bb0090]). HDAC inhibitors may be used in combination with vehicle and/or natural/synthetic scaffolds to regulate the target cells in the aspect of mineral tissue regeneration ([Fig. 5](#f0025){ref-type="fig"}).Fig. 5Application of HDAC inhibitor in bone regeneration in mouse calvarial defect model. The combination of inhibitor, mesenchymal cells and co-polymer scaffold (PCL/PEG) induce new bone formation ([@bb0155]).Fig. 5.

Yet, there are some controversies regarding the effect of HDAC inhibitors. While *in vitro* studies demonstrated that HDAC inhibitors promote osteogenic differentiation, a clinical study reported a decrease in bone mineral density in patients treated with HDAC inhibitors during cancer treatment as well as systemic effect of HDACs inhibition ([@bb0215]). The observed phenotype of smaller pharyngeal teeth in transgenic zebrafish embryos reveals the effects of endocrine disrupting chemicals, such as VPA and TSA. Since HDAC can bind to corepressors of nuclear receptors, it has been proposed that HDAC inhibition disrupts retinoid signaling pathway leading to deficiency of pharyngeal teeth development ([@bb0200]). In heterozygous Runx2 null mice, MS-275, a HDAC class I inhibitor, partially prevents delayed cranial suture closure in cleidocranial dysplasia disorder. This effect was related to the decreased number of progenitor cells as well as the delayed osteogenic differentiation in Runx2 mutation disorder. MS-275 could compensate for genetic insufficiency of Runx2 in Runx2a −/− mice. Therefore, the use of this drug represents a promising chemopreventive strategy for certain genetic diseases like cleidocranial dysplasia ([@bb0015]).

HDAC 3 conditional knockout mice in osterix-expressing progenitor cells (HDAC 3 CKO~OSX~) were runty and had severe deficits in intramembranous and endochondral bone formation ([@bb0240]). In these mice, bone formation was decreased whereas bone marrow adipocyte differentiation was promoted. Moreover, HDAC 3 conditional knockout mice (HDAC 3 CKO~OCN~) were of normal size and weight but progressively lost trabecular and cortical bone mass with age ([@bb0220]). These findings therefore suggest a positive role of HDAC 3 on osteogenesis. HDAC 3 has been reported to be down-regulated during the onset of osteogenic differentiation of hPDLCs. Treatment with TSA, a pan HDAC inhibitor, enhanced osteogenic differentiation of hPDLCs while it reduced the expression of HDAC 3. These data thus propose an opposite role of HDAC 3 in regulating the osteogenic differentiation of distinctive groups of pre-osteoblasts ([@bb0150]). Since HDACs are active in numerous cell types and tissues, it is important to develop selective inhibitors and targeted delivery methods to control the actions of these enzymes.

6. Conclusion {#s0040}
=============

A precise control of gene expression is essential for proper development, differentiation, function, and homeostasis. Several data indicate a potential role of HDACs and their inhibitors in odonto-osteoblast differentiation and bone remodeling. These enzymes are considered a target for future therapeutic use in patients with bone/tooth defect.
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